Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 4:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 921 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: SCD Clear all

Conditions: Tachyarrhythmias, Sudden Cardiac Death, Heart Failure
Interventions: SJ4 connector and RV high voltage SJ4 lead; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 1,701 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Sickle Cell Disease, Pain
Interventions: Not listed
Lead sponsor: Connecticut Children's Medical Center; Other
Eligibility: 7 Years to 21 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Sickle Cell Disease
Interventions: Zileuton; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 12 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Myocardiopathies, Ischemia, Myocardial, Arrythmia, Death, Sudden, Cardiac
Interventions: Not listed
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Sudden Cardiac Death, Ventricular Tachycardia, Ventricular Fibrillation, Cardiomyopathy
Interventions: Cardiac Sympathetic Denervation (CSD), Routine Care; Procedure · Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Los Angeles, California • Portland, Oregon • Nashville, Tennessee

Conditions: Sickle Cell Disease, Sickle Cell Anemia, Osteonecrosis, Ischemic Necrosis, Avascular Necrosis
Interventions: Alendronate Sodium; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Sickle Cell Disease
Interventions: Ticagrelor, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 30 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Miami, Florida • Bethesda, Maryland • Charleston, South Carolina

Conditions: To Assess the Safety and Tolerabiltiy of an Amino Acid Composition in Subjects With Sickle Cell Disease, Anemia, Sickle Cell, Sickle Cell Anemia, Sickle Cell Disorders, Sickle Cell Disease
Interventions: AXA4010; Dietary Supplement
Lead sponsor: Axcella Health, Inc; Industry
Eligibility: 12 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 4
States / cities: Hollywood, Florida • Miami, Florida • Atlanta, Georgia + 1 more

Conditions: Sickle Cell Disease
Interventions: Daratumumab, Alemtuzumab, Sirolimus, Total Body Irradiation; Drug · Radiation
Lead sponsor: Children's National Research Institute; Other
Eligibility: 2 Years to 25 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2054
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Sickle Cell Disease
Interventions: Fludarabine monophosphate, Rituximab, Busulfan, ATG, Cyclophosphamide, Mycophenolate mofetil, Tacrolimus; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Sickle Cell Disease, Vaso-occlusive Crisis
Interventions: Virtual Reality Therapy; Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 6 Years to 25 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 2
States / cities: Memphis, Tennessee

Conditions: Sickle Cell Disease
Interventions: Blood draw, Nasopharyngeal wash; Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 1 Year and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Healthy, Sickle Cell Disease
Interventions: Not listed
Lead sponsor: Bioverativ Therapeutics Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: HEMOGLOBIN SC DISEASE
Interventions: Mg Pidolate, Placebo; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 2
States / cities: Boston, Massachusetts • Houston, Texas

Conditions: Thalassemia, Sickle Cell Disease, Healthy Controls
Interventions: Hydroxyurea, Acetazolamide; Drug
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 7 Years and older
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Sickle Cell Disease
Interventions: Red Blood Cell, Standard of care; Biological · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 20
States / cities: Tuscaloosa, Alabama • Oakland, California • Washington D.C., District of Columbia + 15 more

Conditions: Sickle Cell Disease (SCD)
Interventions: Crizanlizumab (SEG101), Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 5
States / cities: Atlanta, Georgia • Boston, Massachusetts • Charlotte, North Carolina + 2 more

Conditions: Sickle Cell Disease
Interventions: massage, relaxation; Procedure · Behavioral
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 15 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 2
States / cities: Los Angeles, California • Tampa, Florida

Conditions: Cardiomyopathy
Interventions: contrast-enhanced cardiac MRI; Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Acute on Chronic Systolic Congestive Heart Failure, Cardiorenal Syndrome
Interventions: Selective Cytopheretic Device; Device
Lead sponsor: SeaStar Medical; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Anemia, Sickle Cell
Interventions: Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Duarte, California

Conditions: Sickle Cell Disease, Adverse Childhood Experiences, Breastfeeding
Interventions: Breastfeeding support group, Observation; Behavioral · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Sickle Cell Disease, Asthma, Acute Chest Syndrome
Interventions: Budesonide inhalation suspension; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 1 Year to 4 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Sickle Cell Disease
Interventions: Evaluation of cognitive and pre-academic skills, Parent questionnaires; Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 48 Months to 68 Months
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Memphis, Tennessee

Search by objective public record fields.

SJ4 Post Approval Study in Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Therapy Defibrillator Patients

Psychometric Evaluation of the IPPAQ in Pediatric Patients With Sickle Cell Disease Hospitalized With Vasoocclusive Pain

Trial of Zileuton CR in Children and Adults With Sickle Cell Disease

Extracellular Matrix Marker of Arrhythmia Risk (EMMA)

Cardiac Sympathetic Denervation for Prevention of Ventricular Tachyarrhythmias

Alendronate for Osteonecrosis in Adults With Sickle Cell Disease

A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease

To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease

Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody

A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease

Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease

A New Reagent Assay Examining Natural Parvovirus B19 Infection in Sickle Cell Disease

Study of Methodologies to Measure Blood Flow and Oxygenation in Adults With Sickle Cell Disease

Oral Magnesium Pidolate, Hemoglobin SC Disease, MG Pidolate

Cerebrovascular Reserve and White Matter Disease in Patients with Chronic Anemia

Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)

Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients

Home Based Massage and Relaxation for Sickle Cell Pain

Morphological Predictors of Sudden Cardiac Death in Patients With Known Cardiomyopathies

Feasibility of the SCD in Cardiorenal Syndrome Patients Awaiting LVAD

CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease

Early Life Exposures Among Children With Sickle Cell Disease

Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial

Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease